The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.
about
Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-AnalysisOperations research in global health: a scoping review with a focus on the themes of health equity and impactCost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the UK: systematic review and economic evaluation.Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013Economic evaluation of HBV vaccination: A systematic review of recent publications (2000-2013).A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model.Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.HBV infection is associated with greater mortality in hospitalised patients compared to HCV infection or alcoholic liver disease.High treatment modification rates with lamivudine therapy in HBV-infected patients with low baseline viremia and early virological response: A multicenter study.Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma.Retrospective analysis of total direct medical costs associated with hepatitis B patients with oral antiviral versus pegylated interferon therapy in Turkey.Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey.
P2860
Q26765932-F46F2BC6-1562-4F6E-856F-D7067DCF0E53Q29994616-36019FA1-6200-4BF1-963F-0C3AC383CE5BQ30368481-41A7B494-CDE6-4EBD-A5D4-6E805B6D2073Q37135465-C46578B4-F6D5-4E1E-9B8F-DEE2C8299680Q37264961-F16C1B2F-CA91-40B3-8E23-3282ACC84F58Q37387494-48E38E6A-87DC-4126-B0D4-64BB2F493FA6Q40679543-D4C8B440-38BA-4D50-A889-160CBF174B52Q41197534-B18BCA47-2632-445D-8ED8-5308578D0D16Q41467947-15F0C900-D664-4AFB-92FF-47E6DD654FF2Q42210690-33DD184C-5A26-4EC6-B59C-465687875E50Q42236429-91A50E73-89AA-4AEF-BE21-8015D0724575Q47614576-38652764-E90B-4BCE-BEB2-7310F5677FC7
P2860
The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The cost-effectiveness of trea ...... mic and middle income country.
@ast
The cost-effectiveness of trea ...... mic and middle income country.
@en
type
label
The cost-effectiveness of trea ...... mic and middle income country.
@ast
The cost-effectiveness of trea ...... mic and middle income country.
@en
prefLabel
The cost-effectiveness of trea ...... mic and middle income country.
@ast
The cost-effectiveness of trea ...... mic and middle income country.
@en
P2093
P2860
P1476
The cost-effectiveness of trea ...... mic and middle income country.
@en
P2093
Aydan Kansu
Cihan Yurdaydin
Fatih Oguz Onder
Gokhan Kabacam
Jan Hendrik Richardus
Mehlika Toy
Meral Akdogan
Mithat Bozdayi
Ramazan Idilman
Solko Schalm
P2860
P2888
P304
P356
10.1007/S10198-012-0413-8
P577
2012-07-20T00:00:00Z